Zhejiang maker of vitamin A, vitamin E and antibiotic active ingredients, with a growing biologics investment arm.
Zhejiang maker of vitamin A, vitamin E and antibiotic active ingredients, with a growing biologics investment arm.
Sells vitamin A and E mostly into the animal-feed trade, where a handful of Chinese and European producers set global supply and prices swing with each plant's output and demand. Antibiotic ingredients are a second commodity-style line.
In one line: A Chinese vitamin/antibiotic API maker.
Moat: narrow (scale). Large-scale integrated vitamin API production is capital-intensive and slow for new entrants to match.
Headquarters: Shaoxing, Zhejiang, China · Employees: 5,417
Size Zhejiang Medicine (600216.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.51B, the 1506th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.47 on 18 Nov 2026.
Performance Over six months the shares fell 26.1%, against -1.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 5.9% over the last twelve months (peer median +11.3%); the operating margin is 7.0% (peer median 16.4%).
Valuation It trades at 11.5× forward earnings against a peer median of 20.6× (4th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.6 points above its cost of capital (6.4% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥8.43B | CN¥8.84B | CN¥9.33B | CN¥7.76B | CN¥8.08B |
| Revenue growth | — | -5% | +20% | -4% | — |
| Gross profit | CN¥3.20B | CN¥2.82B | CN¥3.72B | CN¥2.29B | CN¥2.53B |
| EBITDA | n/a | CN¥1.64B | CN¥2.02B | CN¥757M | CN¥1.14B |
| Net income | CN¥633M | CN¥873M | CN¥1.16B | CN¥430M | CN¥540M |
| Free cash flow | CN¥460M | CN¥1.44B | CN¥535M | -CN¥162M | -CN¥454M |
| Capital expenditure | CN¥532M | CN¥446M | CN¥689M | CN¥797M | CN¥976M |
| Total debt | CN¥993M | CN¥1.00B | CN¥807M | CN¥857M | CN¥899M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Medicine 600216.SS | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% |
| Zhejiang NHU 002001.SZ | $11.8B | -22% | +11% | 33% | 9.7× | -8.3% |
| Xiamen Kingdomway 002626.SZ | $1.45B | -3% | -3% | 11% | 27.2× | n/a |
| DSM-Firmenich DSFIR.AS | $27.5B | +47% | -45% | 8% | 28.6× | 23.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600216.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.0% | -1.2% | 2nd lowest of 21 |
| 6-month return | -26.1% | -1.6% | 2nd lowest of 21 |
| Distance from 52-week high | -43.6% | -23.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | -5.9% | +11.3% | 4th lowest of 21 |
| Operating margin | 7.0% | 16.4% | 5th lowest of 21 |
| Forward P/E | 11.5× | 20.6× | 4th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -7.8% | 2.8% | 3rd least demanding of 19 |
| Growth delivered (Del g) | +3.9% | +10.5% | 4th lowest of 19 |
| Hurdle (Req g minus delivered) | -11.7 pp | -10.7 pp | 10th least demanding of 19 |
| ROIC minus cost of capital | +2.6 pp | +4.1 pp | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% | +4.4% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.03B | -19% | -1% | 4% | 6.2× | -2.1% | +7.1% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% | +11.6% |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% | +5.3% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| By-health 300146.SZ | China | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% | +0.6% |